Drugs / QIV-SD
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT05624606 Comparator | Nov 2022 → Mar 2024 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 1/2 | NCT03233217 Comparator | Sep → Nov 2017 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QIV-SD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05624606 ↗ |
| Modality | Vaccine | “local standard-dose Quadrivalent Influenza Vaccine (QIV-SD)” NCT03233217 ↗ |
| Route | Subcutaneous | “QIV-SD by SC route” NCT03233217 ↗ |